Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment. The closing of the financing round, led by life science investors SV Health Investors and Johnson & Johnson Innovation, brings total funds raised to over $95 million. The funding is set to support the Phase I STARLYS clinical study evaluating MST-0312, which is anticipated to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!